Warning Letter — Active Cosmetics Manufacturing Inc.
The FDA issued a Warning Letter to Active Cosmetics Manufacturing Inc. following a review by the Center for Drug Evaluation and Research (CDER).
This notice affects Active Cosmetics Manufacturing Inc., as well as personnel involved in regulatory compliance, quality management, and manufacturing operations within the organization.
The issuance of a Warning Letter by CDER indicates that the FDA has identified significant violations of regulatory requirements, which may involve Current Good Manufacturing Practice (CGMP) deviations. This suggests potential risks to product quality and may result in further administrative or legal action if the identified deficiencies are not remediated to the agency's satisfaction.
Regulatory and QA teams should review current manufacturing practices against CGMP standards and ensure all facility registrations and product listings are current. Immediate internal audits of any facilities specifically mentioned in enforcement actions are recommended to identify potential compliance gaps.
FDA Warning Letter issued to: Active Cosmetics Manufacturing Inc.. 04/22/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/active-cosmetics-manufacturing-inc-722408-04222026
Open in openFDA / FDA.gov